Johnson & Johnson (JNJ) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal first quarter ended March 29, 2026. Johnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. The company is a large accelerated filer. Notable strategic developments include the ongoing planned separation of the Orthopaedics business (announced October 2025) and the integration of the Intra-Cellular Therapies acquisition (completed April 2025), which added the product CAPLYTA to the portfolio.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Sales to Customers | $24.06 Billion | $21.89 Billion | +9.9% |
| Gross Profit | $15.96 Billion | $14.54 Billion | +9.8% |
| Gross Margin | 66.3% | 66.4% | -0.1 pts |
| Net Earnings | $5.24 Billion | $11.00 Billion | -52.4% |
| Diluted EPS | $2.14 | $4.54 | -52.9% |
| Operating Cash Flow | $2.51 Billion | $4.17 Billion | -40.0% |
| Cash & Equivalents | $21.69 Billion | $38.47 Billion | -43.6% |
| Total Debt | $55.0 Billion | $52.3 Billion | +5.2% |
| Effective Tax Rate | 12.6% | 19.3% | -6.7 pts |
Material Changes vs. Prior Period
- Significant Earnings Decline: Net earnings dropped 52.4% year-over-year. This is primarily due to a $7.0 billion reversal of the talc litigation reserve recorded in Q1 2025, which inflated prior-year earnings. Q1 2026 included a $0.3 billion charge for talc matters.
- Revenue Growth: Worldwide sales grew 9.9% (6.4% operational growth, 3.5% currency impact). Growth was driven by oncology products (DARZALEX, CARVYKTI) and the new CAPLYTA product, partially offset by a 59.7% decline in STELARA sales due to biosimilar competition.
- Segment Performance:
- Innovative Medicine: Sales up 11.2% to $15.4 billion. Oncology grew 22.8%, while Immunology declined 8.8% (driven by STELARA).
- MedTech: Sales up 7.7% to $8.6 billion. Cardiovascular grew 13.0%, while Orthopaedics grew 6.3%.
- Debt and Liquidity: Total debt increased to $55.0 billion, driven by higher short-term borrowings ($17.5 billion in current debt vs. $8.5 billion prior year). Cash balances decreased significantly due to share repurchases ($4.0 billion) and dividends ($3.1 billion).
Guidance, Outlook, and Risks
- Orthopaedics Separation: The company targets completion of the Orthopaedics business separation within 18 to 24 months of the October 2025 announcement. Restructuring costs for the Surgery franchise are estimated at $0.9–$1.0 billion total.
- Biosimilar Pressure: Continued revenue erosion is expected for STELARA globally. Biosimilar competition for SIMPONI is anticipated in 2026 (Europe H1, U.S. H2), and generic competition for OPSUMIT is expected in the U.S. H2 2026.
- Legal Contingencies:
- Talc Litigation: Approximately 75,000 plaintiffs remain in pending U.S. lawsuits. The company maintains a reserve of approximately $3.4 billion.
- Patent Litigation: Ongoing challenges for key products including XARELTO, INVEGA SUSTENNA, and CAPLYTA. Several settlements were reached in Q1 2026.
- Government Investigations: Active False Claims Act investigations regarding off-label promotion of HIV products and management services for rheumatology practices.
- Capital Allocation: The company repurchased $4.0 billion of common stock in Q1 2026 and declared a quarterly dividend of $1.34 per share (payable June 2026).
Investor Verification Checklist
- Talc Reserve Adequacy: Verify the sufficiency of the $3.4 billion talc reserve given the ongoing volume of litigation (75,000 plaintiffs) and recent court rulings on causation.
- STELARA Decline Trajectory: Monitor the rate of STELARA sales erosion as biosimilar launches accelerate globally; assess the impact on Immunology segment margins.
- Orthopaedics Separation Timeline: Track progress on the planned spin-off to ensure it meets the 18-24 month target and does not incur unexpected transaction costs.
- Debt Maturity Profile: Review the $55 billion debt load, specifically the $17.5 billion in current debt (commercial paper), to assess refinancing risks in a higher interest rate environment.
- Patent Cliff Exposure: Evaluate the status of patent litigation for XARELTO and INVEGA SUSTENNA, as loss of exclusivity would materially impact future revenue.